GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » Institutional Ownership

TWi Biotechnology (ROCO:6610) Institutional Ownership : 0.14% (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TWi Biotechnology's institutional ownership is 0.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TWi Biotechnology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TWi Biotechnology's Float Percentage Of Total Shares Outstanding is 0.00%.


TWi Biotechnology Institutional Ownership Historical Data

The historical data trend for TWi Biotechnology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology Institutional Ownership Chart

TWi Biotechnology Historical Data

The historical data trend for TWi Biotechnology can be seen below:

2018-08-31 2018-09-30 2018-10-31 2018-11-30 2018-12-31 2019-01-31 2019-02-28
Institutional Ownership 0.14 0.14 0.14 0.14 0.14 0.14 0.14

TWi Biotechnology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


TWi Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology Headlines

No Headlines